BioCentury | Nov 9, 2015
Company News

Advanomics, Sunshine Biopharma deal

...not respond to inquiries, and Advanomics could not be reached. Advanomics Corp. , Montreal, Quebec Sunshine Biopharma Inc....
BioCentury | May 5, 2014
Financial News

Sunshine Biopharma financial update

...a two-year share purchase agreement for up to $2.5 million with Dutchess Opportunity Fund II. Sunshine Biopharma Inc....
BioCentury | Dec 9, 2013
Company News

Sunshine Biopharma cancer news

...a small molecule topoisomerase II (TOP2) inhibitor, is in preclinical development to treat cancer. Sunshine Biopharma Inc....
BioCentury | Sep 2, 2013
Company News

Advanomics, Sunshine Biopharma, Laboratoires Garmen Inc. deal

...provide details, and Garmen could not be reached for details. Advanomics Corp. , Montreal, Quebec Sunshine Biopharma Inc....
BioCentury | Dec 3, 2012
Company News

Sunshine Biopharma, Institut National des Sciences Appliquees de Lyon deal

...preclinical development to treat cancer, including small cell lung cancer (SCLC) (see BioCentury, July 9). Sunshine Biopharma Inc....
BioCentury | Jul 9, 2012
Clinical News

Sunshine Biopharma preclinical data

...SCLC tumor cells than generic etoposide. Adva-27a is a small molecule topoisomerase II (TOP2) inhibitor. Sunshine Biopharma Inc....
BioCentury | Jul 18, 2011
Clinical News

Sunshine Biopharma preclinical data

...human breast cancer cells than etoposide. Adva-27a is a small molecule topoisomerase II (TOP2) inhibitor. Sunshine Biopharma Inc....
BioCentury | Jun 27, 2011
Company News

Sunshine Biopharma, Jewish General Hospital deal

...treat cancer. Adva-27a is a small molecule topoisomerase II (TOP2) inhibitor. Details were not disclosed. Sunshine Biopharma Inc....
BioCentury | Jan 31, 2011
Company News

Sunshine Biopharma, Binghamton University deal

...for royalties on the developed IP. Adva-27a is a small molecule topoisomerase II (TOP2) inhibitor. Sunshine Biopharma Inc....
Items per page:
1 - 9 of 9
BioCentury | Nov 9, 2015
Company News

Advanomics, Sunshine Biopharma deal

...not respond to inquiries, and Advanomics could not be reached. Advanomics Corp. , Montreal, Quebec Sunshine Biopharma Inc....
BioCentury | May 5, 2014
Financial News

Sunshine Biopharma financial update

...a two-year share purchase agreement for up to $2.5 million with Dutchess Opportunity Fund II. Sunshine Biopharma Inc....
BioCentury | Dec 9, 2013
Company News

Sunshine Biopharma cancer news

...a small molecule topoisomerase II (TOP2) inhibitor, is in preclinical development to treat cancer. Sunshine Biopharma Inc....
BioCentury | Sep 2, 2013
Company News

Advanomics, Sunshine Biopharma, Laboratoires Garmen Inc. deal

...provide details, and Garmen could not be reached for details. Advanomics Corp. , Montreal, Quebec Sunshine Biopharma Inc....
BioCentury | Dec 3, 2012
Company News

Sunshine Biopharma, Institut National des Sciences Appliquees de Lyon deal

...preclinical development to treat cancer, including small cell lung cancer (SCLC) (see BioCentury, July 9). Sunshine Biopharma Inc....
BioCentury | Jul 9, 2012
Clinical News

Sunshine Biopharma preclinical data

...SCLC tumor cells than generic etoposide. Adva-27a is a small molecule topoisomerase II (TOP2) inhibitor. Sunshine Biopharma Inc....
BioCentury | Jul 18, 2011
Clinical News

Sunshine Biopharma preclinical data

...human breast cancer cells than etoposide. Adva-27a is a small molecule topoisomerase II (TOP2) inhibitor. Sunshine Biopharma Inc....
BioCentury | Jun 27, 2011
Company News

Sunshine Biopharma, Jewish General Hospital deal

...treat cancer. Adva-27a is a small molecule topoisomerase II (TOP2) inhibitor. Details were not disclosed. Sunshine Biopharma Inc....
BioCentury | Jan 31, 2011
Company News

Sunshine Biopharma, Binghamton University deal

...for royalties on the developed IP. Adva-27a is a small molecule topoisomerase II (TOP2) inhibitor. Sunshine Biopharma Inc....
Items per page:
1 - 9 of 9